'This is a walking test, not a talking test': The six minute walking test in congestive heart failure

European Heart Journal

Volumn 26, Issue 8, 2005, Pages 749-750

  Refsgaard, Jens ^a  

^a VIBORG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

CONGESTIVE HEART FAILURE; DAILY LIFE ACTIVITY; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; DYSPNEA; EDITORIAL; EXERCISE; EXERCISE TEST; FATIGUE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WALKING; WALKING TEST;

EXERCISE TEST; EXERCISE TOLERANCE; HEART FAILURE, CONGESTIVE; HUMANS; WALKING;

EID: 17444385219     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi207     Document Type: Editorial

References (11)

1. Brubaker PH. Exercise intolerance in congestive heart failure: a lesson in exercise physiology. J Cardiopulm Rehabil 1997;17:217-221.
2. Olsson LG, Swedberg K, Clark AL et al. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J 2005;26:778-793. First published on March 17, 2005, doi:10.1093/eurheartj/ ehi162.
3. Hiatt WR. Exercise physiology in cardiovascular diseases. Curr Opin Cardiol 1991;6:745-749.
4. Metra M, Nodari S, Raccagni D et al. Maximal and submaximal exercise testing in heart failure. J Cardiovasc Pharmacol 1998;32(Suppl. 1): S36-S45.
5. Packer M, Colucci WS, Sackner-Bernstein et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996;94:2793-2799.
6. Bittner V, Weiner DH, Yusuf S et al., for the SOLVD Investigators. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA 1993;270:1702-1707.
7. Opasich C, Pinna GD, Mazza A et al. Reproducibility of the six-minute walking test in patients with heart failure: practical implications. Am J Cardiol 1998;81:1497-1500.
8. Yusuf S, Tsuyuki R. Using exercise endpoints in heart failure trials: design considerations. Eur Heart J 1996;17:4-6.
9. Guyatt GH, Sullivan MJ, Thompson PJ et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-923.
10. Narang R, Swedberg K, Cleland JG. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J 1996;17:120-134.
11. Maurer M, Katz SD, LaManca J et al. Dissociation between exercise hemodynamics and exercise capacity in patients with chronic heart failure and marked increase in ejection fraction after treatment with beta-adrenergic receptor antagonists. Am J Cardiol 2003;91:356-360.